InnoCan PharmaHAM:IP40 64 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 64/100 and a GF Value™ of €7.83 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,173 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 85251.41% on this metric.
InnoCan Pharma's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for InnoCan Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:
HAM:IP40's 5-Year Yield-on-Cost % is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 3.41 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
InnoCan Pharma 5-Year Yield-on-Cost % Related Terms
HAM:IP40 vs PG, CL, KVUE: 5-Year Yield-on-Cost % Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma 5-Year Yield-on-Cost % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of InnoCan Pharma is calculated as
InnoCan Pharma (HAM:IP40) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #999999 out of 1173 companies in the Consumer Packaged Goods industry.
Is InnoCan Pharma's 5-Year Yield-on-Cost % too high?
InnoCan Pharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, InnoCan Pharma ranks #999999 out of 1173 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's 5-Year Yield-on-Cost % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #999999 out of 1173 companies for 5-Year Yield-on-Cost %. This places InnoCan Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Consumer Packaged Goods company?
The median 5-Year Yield-on-Cost % among Consumer Packaged Goods companies is 3.41, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median 5-Year Yield-on-Cost % is 3.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.83, compared to a current price of €1.75 — trading 77.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. InnoCan Pharma's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.75 is trading 77.7% below its estimated GF Value™ of €7.83.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
5-Year Yield-on-Cost %: 0.00
GF Value™: €7.83 vs. price of €1.75 (77.7% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
64GF Score
Get the complete analysis for HAM:IP40
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 